A detailed history of Janus Henderson Group PLC transactions in Ardelyx, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 25,949,323 shares of ARDX stock, worth $156 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
25,949,323
Previous 22,048,006 17.69%
Holding current value
$156 Million
Previous $161 Million 19.47%
% of portfolio
0.11%
Previous 0.09%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$5.89 - $9.31 $23 Million - $36.3 Million
3,901,317 Added 17.69%
25,949,323 $192 Million
Q1 2024

May 15, 2024

SELL
$6.05 - $9.74 $15.8 Million - $25.4 Million
-2,610,814 Reduced 10.59%
22,048,006 $161 Million
Q4 2023

Feb 14, 2024

SELL
$3.29 - $6.64 $8.63 Million - $17.4 Million
-2,623,801 Reduced 9.62%
24,658,820 $153 Million
Q3 2023

Nov 14, 2023

BUY
$3.3 - $4.83 $18 Million - $26.4 Million
5,455,941 Added 25.0%
27,282,621 $111 Million
Q2 2023

Aug 14, 2023

SELL
$3.23 - $4.95 $920,294 - $1.41 Million
-284,921 Reduced 1.29%
21,826,680 $74 Million
Q1 2023

May 15, 2023

BUY
$2.68 - $4.79 $6.26 Million - $11.2 Million
2,337,268 Added 11.82%
22,111,601 $106 Million
Q4 2022

Feb 14, 2023

BUY
$1.22 - $2.85 $14.1 Million - $32.8 Million
11,520,955 Added 139.59%
19,774,333 $56.4 Million
Q3 2022

Nov 14, 2022

BUY
$0.59 - $1.44 $4.87 Million - $11.9 Million
8,253,378 New
8,253,378 $9.86 Million
Q3 2021

Nov 16, 2021

SELL
$1.27 - $8.17 $740,241 - $4.76 Million
-582,867 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$6.55 - $8.98 $266,034 - $364,731
40,616 Added 7.49%
582,867 $4.42 Million
Q1 2021

May 17, 2021

BUY
$6.1 - $7.69 $1.25 Million - $1.58 Million
204,918 Added 60.75%
542,251 $3.59 Million
Q4 2020

Feb 16, 2021

BUY
$5.05 - $7.1 $1.7 Million - $2.4 Million
337,333 New
337,333 $2.18 Million

Others Institutions Holding ARDX

About ARDELYX, INC.


  • Ticker ARDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 154,636,000
  • Market Cap $928M
  • Description
  • Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...
More about ARDX
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.